Robot Partial Prostatectomy for Anterior Cancer: Long-term Functional and Oncological Outcomes at 7 Years.

Focal therapy Image-guided intervention Magnetic resonance imaging Minimally invasive surgery Prostate cancer Prostatectomy Robotic surgery

Journal

European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568

Informations de publication

Date de publication:
Sep 2023
Historique:
accepted: 06 07 2023
medline: 31 7 2023
pubmed: 31 7 2023
entrez: 31 7 2023
Statut: epublish

Résumé

Partial prostatectomy has been described as an alternative to focal ablation therapy for the management of localized low- to intermediate-risk prostate cancer. This report aims to describe the long-term outcomes in a series of 28 men (2000-2022) who underwent robotic-assisted anterior partial prostatectomy (APP) for anteriorly located tumors entirely or partially within the anterior fibromuscular stroma. The median follow-up is 7 yr (interquartile range [IQR]: 4.2-8). The median prostate-specific antigen (PSA) before APP was 9.6 (6-11). Continence remained uninterrupted in 92% of patients. Erectile function without drug remained uninterrupted in 69%. The median nadir PSA after APP was 0.36 ng/ml (IQR: 0.25-0.60). Cancer recurrence at biopsies at the margins of the primary cancer resected area in case of a PSA elevation was observed in eight patients and led to salvage completion robotic radical prostatectomy at a median time of 3.25 yr (IQR: 2.4-6). Freedom from post-APP cancer recurrence at 7 yr was 62.7% (35.0-81.3%). Pre-APP tumor volume at magnetic resonance imaging (MRI) and volume of grade 4/5 were predictive of recurrence. Freedom from biochemical recurrence after completion radical prostatectomy at 7 yr was 94.7% (68.1-99.3%). All 28 patients are alive. No one had systemic treatment or metastases. These results confirm our initial report of robotic APP with good functional results and acceptable oncological results. The use of the inclusion criteria of pre-APP tumor volume at MRI <3 cc may decrease the risk of recurrence. In this report, we looked at outcomes for infrequent cases of anterior prostate cancer treated with anterior partial prostatectomy, an uncommon surgical procedure as an alternative to in situ focal ablation therapy, to better preserve functional outcomes as compared with whole gland therapy. We found that functional outcomes of uninterrupted continence and erectile function were good. Out of 28 patients, eight had recurrence in the remaining prostate and were treated with a second surgical procedure, radical prostatectomy, which was feasible. We conclude that this new technique is feasible with good functional results and acceptable oncological results, which can be shared with the patients.

Identifiants

pubmed: 37521072
doi: 10.1016/j.euros.2023.07.001
pii: S2666-1683(23)00371-3
pmc: PMC10374895
doi:

Types de publication

Journal Article

Langues

eng

Pagination

11-14

Informations de copyright

© 2023 Published by Elsevier B.V. on behalf of European Association of Urology.

Références

J Urol. 2020 Oct;204(4):741-747
pubmed: 32898975
Eur Urol. 2022 Nov;82(5):551-558
pubmed: 35970657
Eur Urol. 2020 Oct;78(4):583-591
pubmed: 32747200
Urology. 2011 Dec;78(6):1356-62
pubmed: 21840577
BJU Int. 2017 Jun;119(6):968-974
pubmed: 28111893
Eur Urol Focus. 2020 Mar 15;6(2):227-230
pubmed: 31983662
J Urol. 2021 Sep;206(3):638-645
pubmed: 33890485
J Urol. 2019 Nov;202(5):952-958
pubmed: 31144591
Eur Urol. 2017 Sep;72(3):333-342
pubmed: 27613061

Auteurs

Arnauld Villers (A)

Department of Urology, CHU Lille, Univ. Lille, Lille, France.
UMR9020-U1277 - CANTHER, CNRS, Inserm, Institut Pasteur de Lille, CHU Lille, Univ. Lille, Lille, France.

Denis Seguier (D)

Department of Urology, CHU Lille, Univ. Lille, Lille, France.
UMR9020-U1277 - CANTHER, CNRS, Inserm, Institut Pasteur de Lille, CHU Lille, Univ. Lille, Lille, France.

Philippe Puech (P)

Department of Radiology, CHU Lille, Univ. Lille, Lille, France.

Georges-Pascal Haber (GP)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Mihir M Desai (MM)

Catherine & Joseph Aresty Department of Urology, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Sebastien Crouzet (S)

Department of Urology, Edouard Herriot Hospital, University of Lyon, Lyon, France.

Xavier Leroy (X)

Department of Pathology, CHU Lille, Université de Lille, Lille, France.

Julien Labreuche (J)

Department of Biostatistics, CHU Lille, Lille, France.
ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, CHU Lille, University of Lille, Lille, France.

Inderbir S Gill (IS)

Catherine & Joseph Aresty Department of Urology, USC Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Jonathan Olivier (J)

Department of Urology, CHU Lille, Univ. Lille, Lille, France.
UMR9020-U1277 - CANTHER, CNRS, Inserm, Institut Pasteur de Lille, CHU Lille, Univ. Lille, Lille, France.

Classifications MeSH